Prospective, multicenter surveillance study of Candida glabrata:: Fluconazole and Itraconazole susceptibility profiles in bloodstream, invasive, and colonizing strains and differences between isolates from three urban teaching hospitals in New York City (Candida susceptibility trends study, 1998 to 1999)

被引:33
作者
Safdar, A
Chaturvedi, V
Koll, BS
Larone, DH
Perlin, DS
Armstrong, D
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Med, Infect Dis Serv, New York, NY 10021 USA
[2] Cornell Univ, Weill Med Coll, Dept Med, New York, NY USA
[3] Beth Israel Med Ctr, Dept Med, Div Infect Dis, New York, NY 10003 USA
[4] Cornell Univ, New York Weill Med Ctr, Clin Microbiol Lab, New York, NY USA
[5] Publ Hlth Res Inst City New York Inc, New York, NY 10016 USA
[6] New York State Dept Hlth, Mycol Lab, Albany, NY USA
关键词
D O I
10.1128/AAC.46.10.3268-3272.2002
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Since the 1990s, the substantial increase in the rate of Candida glabrata infections has become a serious problem. As most C glabrata infections arise from the host's endogenous microflora, the present prospective, multicenter analysis included all clinical isolates associated with colonization and with systemic and hematogenous candidiasis. Among 347 C. glabrata isolates, the overall rates of resistance to fluconazole (MIC 2: 64 mug/ml) and itraconazolle (MIC greater than or equal to 1 mug/ml) were 10.7 and 15.2%, respectively, although for half (n = 148) of the itraconazole-susceptible isolates the MICs (0.25 to 0.5 mug/ml) were in the susceptible-dependent upon dose range. Fluconazole resistance was more common among C. glabrata isolates obtained from centers caring for patients with cancer (MICs at which 90% of isolates are inhibited [MIC(90)s] = 32 mug/ml) or AIDS (MIC(90)s > 64 mug/ml) than among C. glabrata isolates from a community-based university medical center (MIC(90)s = 16 mug/ml) (P = 0.001). Thirty-three bloodstream isolates and those obtained from other body sites had similar in vitro susceptibility profiles. The fluconazole MIC(90)s (less than or equal to16 mug/ml) for C. glabrata yeast isolates from the gastrointestinal tract were lower than those (greater than or equal to64 mug/ml) for C. glabrata isolates from respiratory and urinary tract samples (P = 0.01). A similar discrepancy for itraconazole was not significant (P > 0.5). We did not observe differences in fluconazole or itraconazole susceptibility profiles among C. glabrata isolates associated with either hematogenous dissemination or colonization. The significant discrepancy in antifungal susceptibility among C. glabrata organisms isolated from hospitals in the same geographic region emphasizes the significance of periodic susceptibility surveillance programs for individual institutions, especially those providing care to patients at risk.
引用
收藏
页码:3268 / 3272
页数:5
相关论文
共 36 条
[21]   Microbiological factors influencing the outcome of nosocomial bloodstream infections: A 6-year validated, population-based model [J].
Pittet, D ;
Li, N ;
Woolson, RF ;
Wenzel, RP .
CLINICAL INFECTIOUS DISEASES, 1997, 24 (06) :1068-1078
[22]   Development of interpretive breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of in vitro in vivo correlation data for fluconazole, itraconazole, and Candida infections [J].
Rex, JH ;
Pfaller, MA ;
Galgiani, JN ;
Bartlett, MS ;
EspinelIngroff, A ;
Ghannoum, MA ;
Lancaster, M ;
Odds, FC ;
Rinaldi, MG ;
Walsh, TJ ;
Barry, AL .
CLINICAL INFECTIOUS DISEASES, 1997, 24 (02) :235-247
[23]  
REX JH, 1995, ANTIMICROB AGENTS CH, V39, P1, DOI 10.1128/AAC.39.1.1
[24]   Infectious morbidity in critically ill patients with cancer [J].
Safdar, A ;
Armstrong, D .
CRITICAL CARE CLINICS, 2001, 17 (03) :531-+
[25]   Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation:: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome [J].
Safdar, A ;
van Rhee, F ;
Henslee-Downey, JP ;
Singhal, S ;
Mehta, J .
BONE MARROW TRANSPLANTATION, 2001, 28 (09) :873-878
[26]   Prospective study of Candida species in patients at a comprehensive cancer center [J].
Safdar, A ;
Chaturvedi, V ;
Cross, EW ;
Park, S ;
Bernard, EM ;
Armstrong, D ;
Perlin, DS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (07) :2129-2133
[27]  
SAFDAR A, IN PRESS BONE MARROW
[28]  
Safdar Amar, 2002, International Journal of Infectious Diseases, V6, P198, DOI 10.1016/S1201-9712(02)90111-6
[29]   Role of ATP-binding-cassette transporter genes in high-frequency acquisition of resistance to azole antifungals in Candida glabrata [J].
Sanglard, D ;
Ischer, F ;
Bille, J .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (04) :1174-1183
[30]   Management of infections caused by Candida glabrata [J].
Jack D. Sobel .
Current Infectious Disease Reports, 2000, 2 (5) :424-428